Batavia Bioservices and Xendo have entered a strategic business collaboration under which all of Xendo’s bioprocess manufacturing activities have been transferred to Batavia. This agreement gives Batavia access to simulated moving bed (SMB) purification technology as well as infrastructure, and microbial process and product development. The companies will establish joint marketing efforts in which Xendo will provide engineering, regulatory and clinical support services and Batavia will provide process development and analytical services.

Menzo Havenga, chief executive officer of Batavia Bioservices, said, “Xendo and Batavia Bioservices together have more critical mass and therefore are able to execute larger, more complex customer programs. It is fully expected that our collaboration will result in more customers being offered a complete development services package.”

André van de Sande, chief executive officer Xendo, said, “I trust that by combining our forces both companies are better positioned to service our customers. This helps Xendo, both in the Netherlands and international, to further expand.”